Open access
Open access
Powered by Google Translator Translator

Oncology - Urological

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

9 Jul, 2021 | 10:03h | UTC

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link to abstract – $ for full-text)

News release: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet

Related articles: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer AND Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer AND Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis AND Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer AND Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer AND Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy AND Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer AND Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis AND Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

 


RCT: Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.

24 Jun, 2021 | 09:41h | UTC

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 


RCT: Adjuvant Nivolumab vs. Placebo in Muscle-Invasive Urothelial Carcinoma.

3 Jun, 2021 | 10:36h | UTC

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma – New England Journal of Medicine

 


AUA Guideline | Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up.

2 Jun, 2021 | 08:27h | UTC

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up – American Urological Association

Commentary: AUA updates guideline on renal masses and localized renal cancer – Urology Times

 


M-A: A biofeedback‐guided program or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy.

26 May, 2021 | 08:13h | UTC

A biofeedback‐guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta‐analysis and systematic review – The International Journal of Clinical Practice

 


RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

10 May, 2021 | 00:46h | UTC

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)

 


Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer

4 May, 2021 | 08:26h | UTC

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

 

Commentary on Twitter

 


AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies

29 Apr, 2021 | 08:33h | UTC

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association – Circulation: Genomic and Precision Medicine

News release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association

Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association

Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay

 


Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review

18 Apr, 2021 | 21:16h | UTC

Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review – The Journal of Urology

Commentary: Review: For many men with prostate cancer, surgery risks outweigh potential benefits – U.S. Department of Veteran Affairs

 


M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy

18 Apr, 2021 | 21:14h | UTC

Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis – The Journal of Urology

 


RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy

18 Apr, 2021 | 21:11h | UTC

Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Nivolumab plus Cabozantinib vs. Sunitinib for Advanced Renal-Cell Carcinoma

4 Mar, 2021 | 08:33h | UTC

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

 


M-A: Local salvage therapies after radiotherapy for prostate cancer

3 Mar, 2021 | 08:06h | UTC

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


RCT: Extended vs. limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer

3 Mar, 2021 | 08:05h | UTC

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial – European Urology (link to abstract – $ for full-text)

Commentary: Extended pelvic lymph node dissection during RP does not appear beneficial – Urology Times

 

Commentary on Twitter

 


Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update

21 Feb, 2021 | 21:47h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging

16 Feb, 2021 | 01:50h | UTC

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study – JAMA Oncology

Commentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)

 

Commentary on Twitter

 


RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

15 Feb, 2021 | 00:36h | UTC

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Immunotherapy – targeted drug combination improves survival in advanced kidney cancer – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

15 Feb, 2021 | 00:34h | UTC

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: 2021 Genitourinary Cancers Symposium: Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma – The ASCO Post

 


RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma

15 Feb, 2021 | 00:32h | UTC

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress

 


Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer

15 Feb, 2021 | 00:31h | UTC

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)

 


RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer

15 Feb, 2021 | 00:29h | UTC

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today

 


RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer

5 Feb, 2021 | 01:27h | UTC

Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary: Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard – Ontario Institute for Cancer Research AND Another Win for MRI and Targeted Prostate Biopsy – MedPage Today (free registration required)

Related: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis – New England Journal of Medicine (study and commentaries) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis – European Urology AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer (studies and commentaries)

 


Stay Updated in Your Specialty

No spam, just news.